USPs that matters:

$kyrocking Ca$hcows

AI triggered Signals

ETF InfoDataHub

Visit our new ATH Index-Gate

White Label as a Service

IPO InfoDataHub

Short Selling Radar

Turnkey solutions: ayondo Franchise

& more ...

Tipp: Hedge Fund Activity Tracker ("HFAT")

Info-Hub

Newswire
Directors Dealings
DD i/o
Short Selling Radar
HFAT
WWR
FTT
NewAD
Ratings
Vola-Statistics

Tools

Tools/Apps
Lab

Campus

Education
Webinars
Mentoring

Press

FAQ

What's New

Company
- About Us
- Vision/Mission
- IR
- Press
- Career
- Specials
Portfolio
Product
- CFD/FX
- Indices
- Currencies
- Commodities
- Metals
- Stocks & ETFs
- Crypto
- ETP/ETI
- Financial Innovations
Platforms
Institutional/B2B

Home
Terminal
Redcare Pharmacy NV

Redcare Pharmacy NV

WHO'M

Digital Profiler. Simply click the AI button

CUSIP

N7975Z103

SEDOL

BYYH7G9

CIK

N/A

www.redcare-pharmacy.com

LEI: 529900JK6UXHY1YKZ082

New: Infographics X-Lab

FIGI: BBG00DSX0K30

RDC

Redcare Pharmacy NV

GICS: 30101010 · Sector: EQTY · Sub-Sector: -

PROFILER

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

Redcare Pharmacy

Click to initiate

ENTERPRISE

NAME

Redcare Pharmacy NV

ISIN

NL0012044747

TICKER

RDC

MIC

XETR

REUTERS

RDC.DE

BLOOMBERG

SAE GR

F&G: 35

5.523,04 S&P · 23,48 Vola-Index · 94.200,51 BTC · 1,13637 EURUSD

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

X-OVR
FACTSHEET
PEERGROUP
X-News Explorer
L/S SHORT
STUDY
ROOTS
IT’s ME

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

Directors Dealings

X-Billboard

EQS Newswire

Globe Newswire

PR Newswire

BusinessWire

ACCESS Newswire

ActuNews

Newsfile

EDGAR

EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.

Tue, 08.04.2025

THIS ANNOUNCEMENT, INCLUDING THE INFORMATION INCLUDED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOUL...

Research & Analysis

Tue, 08.04.2025

Research & Analysis

Tue, 08.04.2025

Research & Analysis

Fri, 04.04.2025

Redcare Pharmacy: fast growth continues in Q1; fully-organic sales growth 28%, Rx sales in Germany up 191% and active customers up 0.6 million. Group sales up 28% or EUR 157M year over year, to EUR 717M in Q1. Rx sales in Germany up 191% to EUR 108M. Non-Rx sales up 20% to EUR 484M. Active customer base up 0.6M in Q1 to 13.1M, 1.9M higher in ...

Research & Analysis

Wed, 02.04.2025

Michael Köhler and Stephan Weber nominated for the Supervisory Board of Redcare Pharmacy. Sevenum, 2 April 2025. At Redcare Pharmacy’s upcoming Annual General Meeting (AGM) on 15 May 2025, changes to the composition of the Supervisory Board will be on the agenda. Redcare Pharmacy nominates the company’s founders and former board members Michael Kö...

Research & Analysis

Tue, 11.03.2025

Building on a successful 2024, Redcare Pharmacy expects margin uplift and unabated fast growth in 2025, including a doubling of Rx. Total sales +32% to EUR 2.4 bn in FY 2024 (Q4, +27%), with DACH +33% (Q4, 27%) and International +26% (Q4, 29%). Non-Rx sales +21% to EUR 1.6 bn (Q4, +22%). Record gain in active customers, up 1.7M to 12.5M, with Ger...

Research & Analysis

Thu, 27.02.2025

Positive judgment of the European Court of Justice strengthens the position of Redcare Pharmacy and its customers. Sevenum, the Netherlands, 27 February 2025 – Redcare Pharmacy welcomes today's judgment of the European Court of Justice that advertising measures that promote the purchase of prescription medicines in the form of direct discounts or...

Research & Analysis

Thu, 09.01.2025

Redcare Pharmacy completes an exceptional year across the Group: 2024 sales up 32% to EUR 2.4bn, with Rx growth in Germany accelerating to 142% in Q4. Full-year sales increase 32% year over year to EUR 2.4bn; 21% growth in non-Rx sales to EUR 1.6bn and 64% growth in total Group Rx sales to EUR 749M. In Q4, total sales rise 27% to EUR 674M; non-...

Research & Analysis

Tue, 05.11.2024

Redcare Pharmacy: strong Q3 growth combined with 2% adj. EBITDA margin. Rx momentum in Germany further increased, with sales growth of over 130% in October. Total Group sales growth 21% in Q3 to EUR 575M and 34% year to date to EUR 1.7bn after nine months. Non-Rx sales growth 20% in Q3 to EUR 383M (9M growth 20% to EUR 1.2bn); Rx sales growth 23%...

Research & Analysis

Thu, 03.10.2024

Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing based on very convincing e-Rx metrics. Q3 total Group sales up 21% year over year to EUR 574M and year to date 34% to EUR 1.7bn; non-Rx sales growth 20% year over year to EUR 383M and also 20% year to date to EUR 1.2bn. Active cus...

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

Legend

SMART * AD

P R O D U C T S U G G E S T I O N S

Report a bug

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Important note

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

Understood and confirmed *

I would like to continue *

Continue

Submit improvement suggestion/new feature

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Link to view/tool

View/Tool (specify URL/link)

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Your opinion is important to us!

FAQ

You are interested

Do you have a request? Get in contact with us

You are already a member?

Who is online? Community stats (Snapshot): 31.376 Visitors - 21.461 Registered members - 18 New registrations (Welcome!)

ayondo® 2025 - Est.: 2008 - Technology provider, social network, trader community and online platform for investors with an affinity for the stock market - Information, data and news network - Multi-award-winning international business model - Proprietary technology - Fintech pioneer and innovation driver for disruptive technologies - Made in Germany | AI First | NextGen-Finovator

Made in Germany

ayondo-prime a²

Useful Links

About Us

Vision/Mission

Imprint

Legal

Data Protection

Cookie Guidelines

Privacy

Contact

MetaTrader 4

MetaTrader 5

ActivTrader

Education

Tools

Product Universe

FAQ

Visual Sitemap

Helpdesk

Fast lane

https://ayon.do/v

https://ayon.do/r

ayondo® - my community, my spirit

Social Media Links

ayondo® is a trademark of RSQ Technology Ventures GmbH ("RSQ"). RSQ is the operator of the Internet presence ayondo.com and its sub-sites. ayondo® as a brand represents a community of interest that is connected via a social network and common interests.

Financial literacy represents a key qualification. A key objective is to promote financial knowledge and financial literacy. The content published on the online portal is aimed at people who are interested in information and education in the field of investment, investing and trading and related topics. As a precautionary measure, we would like to point out that none of the content available on ayondo.com can be interpreted as a recommendation or invitation to buy or sell financial instruments, nor does it constitute any other advisory service. An explicit recommendation to use a particular service, information or financial instruments is not made.

Inasmuch as investment brokerage within the meaning of Section 2 (2) No. 3 of the German Securities Trading Act (WpIG) is provided via the online portal ayondo.com, RSQ acts as a contractually bound broker pursuant to Section 3 (2) WpIG. This service is provided exclusively for the account and under the liability of DonauCapital Wertpapier GmbH, Passauer Str. 5, 94161 Ruderting. In this case, the contractual partner of the customer is exclusively DonauCapital Wertpapier GmbH.

RSQ is entered as a contractually bound intermediary of DonauCapital Wertpapier GmbH in the public register maintained by the Federal Financial Supervisory Authority (BaFin) on the Internet. The register can be viewed at www.bafin.de.

If interested parties wish to take advantage of securities services with reference to CFD or FX trading, there is the option to consider offers from our cooperation partners for this purpose. Provided that this option is used, RSQ will broker trading accounts to the ActivTrades group of companies.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74% and 89% of all retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Consumer information

Imprint

smart.AD

Candlestick Cheatsheet
(02/2023)

Math of Gains and Losses
(02/2023)

FX-Secrets
(02/2023)

Product search
(02/2023)

Risk of Ruin
(03/2023)

KCC
(07/2023)

Trade Calculator
(03/2023)

Suggest a Product
(03/2023)

Quality Matrix
(03/2023)

ChatGPT ayondo
(02/2023)

GPT-FAQ
(03/2023)

MQL AI
(05/2023)

MQL Library
(06/2023)

Visual Sitemap
(06/2023)

DAX-Statistics
(09/2023)

Technical Analysis
(09/2023)

Technical Analysis-pro
(10/2023)

TransparentShare
(11/2023)

Dashboards^pro
(12/2023)

Redcare Pharmacy NV

Redcare successfully executes placement of new convertible bonds and buys back part of the outstanding convertible bonds.

Redcare Pharmacy N.V. successfully places EUR 300 million convertible bonds and repurchases part of its outstanding EUR 225 million 0.00% convertible bonds due 2028

Redcare Pharmacy N.V. launches EUR 300m convertible bonds and invites holders of its outstanding EUR 225m convertible bonds due 2028 to tender their bonds for cash

fast growth continues in Q1; fully-organic sales growth 28%, Rx sales in Germany up 191% and active customers up 0.6 million.

Michael Köhler and Stephan Weber nominated for the Supervisory Board of Redcare Pharmacy.

Building on a successful 2024, Redcare Pharmacy expects margin uplift and unabated fast growth in 2025, including a doubling of Rx.

Positive judgment of the European Court of Justice strengthens the position of Redcare Pharmacy and its customers.

2024 sales up 32% to EUR 2.4bn, with Rx growth in Germany accelerating to 142% in Q4.

strong Q3 growth combined with 2% adj. EBITDA margin. Rx momentum in Germany further increased, with sales growth of over 130% in October.

Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing based on very convincing e-Rx metrics.

Newsletter